A further improvement in this respect could be achieved by using anti-EGFR antibodies optimized to deliver enhanced ADCC activity, which demonstrated a superior anti-tumor activity as compared to cetuximab in mouse models (72). The gene discussed is EGFR; the disease is neoplasm.